The national health department has asked drugmakers to submit prices, and how much they can make, of the two-monthly anti-HIV jab, CAB-LA.
Mia Malan, founder and editor-in-chief of the Bhekisisa Centre for Health Journalism weighs in on whether generic companies will be able to manufacture the drug at a low enough price.